Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.96 |
| ▸ | MAOA | P21397 | 1/20 | 0.79 |
| ▸ | MAOB | P27338 | 1/20 | 0.79 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.79 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.79 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.79 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3520274 | 0.98 | DPP4 (0.92) | DPP4MAOAMAOBTAAR1SLC6A3 | |
| SCHEMBL294582 | 0.98 | DPP4 (1.00) | DPP4MAOAMAOBTAAR1SLC6A3 | |
| Hydrochloric Acid SCHEMBL6809143 | 0.96 | DPP4 (0.96) | DPP4MAOAMAOBTAAR1SLC6A3 | |
| SCHEMBL294970 | 0.93 | DPP4 (0.91) | DPP4MAOAMAOBTAAR1SLC6A3 | |
| Hydrochloric Acid SCHEMBL6809124 | 0.91 | DPP4 (0.88) | DPP4MAOAMAOBTAAR1SLC6A3 | |
| Water SCHEMBL7260926 | 0.91 | DPP4 (0.88) | DPP4MAOAMAOBTAAR1SLC6A3 | |
| SCHEMBL1492704 | 0.89 | MAOB (1.00) | DPP4MAOAMAOBTAAR1SLC6A3 | |
| SCHEMBL3516310 | 0.88 | SLC6A3 (1.00) | DPP4MAOAMAOBTAAR1SLC6A3 | |
| Hydrochloric Acid SCHEMBL6813615 | 0.86 | MAOB (0.95) | DPP4MAOAMAOBTAAR1SLC6A3 | |
| Carbamic Acid SCHEMBL10009301 | 0.84 | DPP4 (0.75) | DPP4MAOAMAOBTAAR1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409917-B2 | Heterocyclic amide derivatives as P2X7 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-08-09 | — | — | US | claimed |
| EP-2804865-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-23 | — | — | EP | claimed |
| US-20150025075-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-01-22 | — | — | US | claimed |
| EP-2804865-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2014-11-26 | — | — | EP | claimed |
| WO-2013108227-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-07-25 | — | — | WO | claimed |
| CN-100379719-C | Substituted aminomethyl-phenyl-cyclohexane derivatives | GRUENENTHAL GMBH (DE) | 2008-04-09 | — | — | CN | claimed |
| US-20070105785-A1 | Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | claimed |
| US-7125848-B2 | Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators | DYNOGEN PHARMACEUTICALS, INC. (US) | 2006-10-24 | — | — | US | claimed |
| US-7041704-B2 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | DYNOGEN PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | claimed |
| EP-1596844-A2 | USE OF SODIUM CHANNEL MODULATORS FOR TREATING GASTROINTESTINAL TRACT DISORDERS | Dynogen Pharmaceuticals Inc. (US) | 2005-11-23 | — | — | EP | claimed |
| EP-1246793-B1 | SUBSTITUTED AMINOMETHYL-PHENYL-CYCLOHEXANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2004-11-10 | — | — | EP | claimed |
| US-20040213842-A1 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | DYNOGEN PHARMACEUTICALS, INC. | 2004-10-28 | — | — | US | claimed |
| US-20040209960-A1 | Methods of treating lower urinary tract disorders using sodium channell modulators | DYNOGEN PHARMACEUTICALS, INC. | 2004-10-21 | — | — | US | claimed |
| WO-2004066987-A2 | USE OF SODIUM CHANNEL MODULATORS FOR TREATING GASTROINTESTINAL TRACT DISORDERS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-08-12 | — | — | WO | claimed |
| WO-2004066990-A2 | METHODS OF TREATING LOWER URINARY TRACT DISORDERS USING SODIUM CHANNEL MODULATORS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-08-12 | — | — | WO | claimed |
| US-6673794-B2 | ANALGESICS, INCOTINENCE, SKIN DISORDERS, ANTIINFLAMMATORY AGENTS | GRUENENTHAL GMBH (DE) | 2004-01-06 | — | — | US | claimed |
| CN-1437576-A | Substituted aminomethyl-phenyl-cyclohexane derivatives | GRUENENTHAL GMBH (DE) | 2003-08-20 | — | — | CN | claimed |
| US-20030069288-A1 | Substituted aminomethyl-phenyl-cyclohexane derivatives | GRUENETHAL GMBH (DE) | 2003-04-10 | — | — | US | claimed |
| EP-1019367-A1 | DERIVATIVES OF 2,5- AND 3,5-DISUBSTITUTED ANILINES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-07-19 | — | — | EP | claimed |
| WO-1999007672-A1 | DERIVATIVES OF 2,5- AND 3,5-DISUBSTITUTED ANILINES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1999-02-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025075-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX1, P2RX3 | DPP4 1268/4885MAOA 1301/4885MAOB 1229/4885 |
| US-20070105785-A1 | Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators | CACNB2, RYR2, FABP2 | DPP4 1254/4885MAOA 3275/4885MAOB 2755/4885 |
| US-20040213842-A1 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | SLC10A2, VIPR2, TRPV1 | DPP4 853/4885MAOA 995/4885MAOB 987/4885 |
| US-20030069288-A1 | Substituted aminomethyl-phenyl-cyclohexane derivatives | PTGER1, CYP2E1, HRH2 | DPP4 2009/4885MAOA 145/4885MAOB 309/4885 |
| US-20040209960-A1 | Methods of treating lower urinary tract disorders using sodium channell modulators | CACNA1G, CACNA1D, CACNA1B | DPP4 1014/4885MAOA 983/4885MAOB 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.